SEHK:1548Life Sciences
Genscript Biotech (SEHK:1548) Stock Near Doubles As Losses Deepen
Genscript Biotech stock has almost doubled over the past 3 months, yet today’s H1 print reminds you that the share price is racing ahead of a business still working through heavy losses. The headline is simple. Revenue sits at US$404.2m for the half while the company posted a net loss of US$129.3m and remains unprofitable on a trailing basis.
The real tension for investors is the valuation. At HK$26.08, Genscript Biotech trades on an 8.6x P/S multiple with a discounted cash flow reference...